Search Results - "Di Francesco, Maria E"

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer by Pettazzoni, Piergiorgio, Viale, Andrea, Shah, Parantu, Carugo, Alessandro, Ying, Haoqiang, Wang, Huamin, Genovese, Giannicola, Seth, Sahil, Minelli, Rosalba, Green, Tessa, Huang-Hobbs, Emmet, Corti, Denise, Sanchez, Nora, Nezi, Luigi, Marchesini, Matteo, Kapoor, Avnish, Yao, Wantong, Francesco, Maria E Di, Petrocchi, Alessia, Deem, Angela K, Scott, Kenneth, Colla, Simona, Mills, Gordon B, Fleming, Jason B, Heffernan, Timothy P, Jones, Philip, Toniatti, Carlo, DePinho, Ronald A, Draetta, Giulio F

“…Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC,…”
Get full text

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma by Vashisht Gopal, Y N, Gammon, Seth, Prasad, Rishika, Knighton, Barbara, Pisaneschi, Federica, Roszik, Jason, Feng, Ningping, Johnson, Sarah, Pramanik, Snigdha, Sudderth, Jessica, Sui, Dawen, Hudgens, Courtney, Fischer, Grant M, Deng, Wanleng, Reuben, Alexandre, Peng, Weiyi, Wang, Jian, McQuade, Jennifer L, Tetzlaff, Michael T, Di Francesco, Maria E, Marszalek, Joe, Piwnica-Worms, David, DeBerardinis, Ralph J, Davies, Michael A

“…The purpose of this study is to determine if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway…”
Get full text

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism by Baran, Natalia, Lodi, Alessia, Sweeney, Shannon Renee, Kuruvilla, Vinitha Mary, Cavazos, Antonio, Herranz, Daniel, Skwarska, Anna, Warmoes, Marc, Davis, Eric, Harutyunyan, Karine, Feng, Ningping, Gay, Jason P, Kaminski, Marcin, Konoplev, Sergej, Jabbour, Elias, Ferrando, Adolfo A., Di Francesco, Maria E, Lorenzi, Philip, Marszalek, Joseph R, Tiziani, Stefano, Konopleva, Marina Y, Renu, Pandey

“…Notch1-mutated T-ALL is an aggressive hematologic malignancy lacking targeted therapeutic options. Genomic alterations in Notch1-gene and its activated…”
Get full text

Abstract 2831: Collateral lethality: A new target for personalized oncology by Lin, Yu-Hsi, Hammoudi, Naima, Satani, Nikunj, Ackroyd, Jeffrey, Khadka, Sunada, Georgiou, Dimitra, Marszalek, Joe, Sun, Yuting, Protopopova, Marina, Francesco, Maria E. Di, Czako, Barbara, Wang, Alan Y., DePinho, Ronald A., Muller, Florian L.

“…Large-scale genomic profiling efforts, such as The Cancer Genome Atlas (TCGA) have painted an unprecedentedly detailed picture of the genetic alterations that…”
Get full text

Abstract 2900: Dissection of clonal heterogeneity unmasks pre-existing chemoresistance and new metabolic vulnerabilities in pancreatic cancer by Seth, Sahil, Li, Chieh-Yuan, Loponte, Sara, Ho, I-Lin, Corti, Denise, Sapio, Luigi, Poggetto, Edoardo Del, Peoples, Michael, Karpinets, Tatiana, Robinson, Frederick S., Jiang, Shan, Dutta, Prasanta, Marszalek, Joseph, Francesco, Maria E. Di, Heffernan, Timothy P., Giuliani, Virginia, Bhattacharya, Pratip K., Genovese, Giannicola, Futreal, Andrew, Draetta, Giulio, Viale, Andrea, Carugo, Alessandro

“…Adaptive drug-resistance mechanisms allow human tumors to evade treatment through selection and expansion of treatment-resistant clones. Modeling the…”
Get full text

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor by Baran, Natalia, Lodi, Alessia, Dhungana, Yogesh, Sweeney, Shannon RENEE, Renu, Pandey, Herbrich, Shelley, Hoff, Fieke W, Skwarska, Anna, Kaplan, Mecit, Kuruvilla, Vinitha Mary, Cavazos, Antonio, Warmoes, Marc, Rojas-Sutterlin, Shanti, Haman, Andre, Veiga, Diogo Troggian, Furudate, Ken, Ma, Helen, Harutyunyan, Karine, Yang, Wentao, Gagea, Mihai, Du, Di, Daher, May, Garcia, Luciana Melo, Piya, Sujan, Ruvolo, Vivian, Shanmugavelandy, Sriram, Feng, Ningping, Gay, Jason P, Havranek, Ondrej, Henderson, Jared, Tomczak, Katarzyna, Kaminski, Marcin, Herranz, Daniel, Ferrando, Adolfo, Jabbour, Elias, Di Francesco, Maria E, Teachey, David T., Horton, Terzah M., Rezvani, Katayoun, Yang, Jun J., Kornblau, Steven M., Davis, Eric, Takahashi, Koichi, Andreeff, Michael, Marszalek, Joseph R, Lorenzi, Philip, Yu, Jiyang, Tiziani, Stefano, Hoang, Trang, Konopleva, Marina

“…The inferior cure rate of T-cell acute lymphoblastic leukemia (T-ALL) is associated with inherent drug resistance. The activating NOTCH1 gene mutations have…”
Get full text

Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer by Evans, Kurt, Moulder, Stacy, Yuca, Erkan, Scott, Stephen, Arango, Natalia Paez, Shariati, Maryam, Vellano, Christopher P, Saridogan, Turcin, Zheng, Xiaofeng, Gonzalez-Angulo, Ana Maria, Zhao, Ming, Su, Xiaoping, Tapia, Coya, Chen, Ken, Akcakanat, Argun, Perou, Charles M, Lim, Bora, Tripathy, Debu, Yap, Timothy A, Francesco, Maria E Di, Draetta, Giulio, Jones, Philip, Marszalek, Joe, Meric-Bernstam, Funda

“…There is a pressing need to identify improved therapies for triple negative breast cancers (TNBC) resistant to standard chemotherapy. To identify potential…”
Get full text

Abstract 3837: Passenger deletion of ENO1 as a collateral lethality target in cancer by Lin, Yu-Hsi, Satani, Nikunj, Hammoudi, Naima, Marszalek, Joe, Sun, Yuting, Protopopova, Marina, Di Francesco, Maria E., Czako, Barbara, Wang, Alan, DePinho, Ronald A., Muller, Florian L.

“…Large scale genomic characterization efforts such as TCGA have painted an unprecedentedly detailed picture of the genetic alterations that underlie…”
Get full text

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition by Baran, Natalia, Lodi, Alessia, Sweeney, Shannon Renee, Renu, Pandey, Kuruvilla, Vinitha Mary, Cavazos, Antonio, Herranz, Daniel, Skwarska, Anna, Warmoes, Marc, Davis, R. Eric, Harutyunyan, Karine, Feng, Ningping, Gay, Jason P, Konoplev, Sergej Naumovich, Kaminski, Marcin, Kovacs, Jeffrey J, Du, Di, Jabbour, Elias J., Ferrando, Adolfo A., Di Francesco, Maria E, Lorenzi, Philip L, Marszalek, Joseph R, Tiziani, Stefano, Konopleva, Marina Y.

“…Adult T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy characterized by limited therapeutic options and a high rate of…”
Get full text

Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance by Sun, Yuting, Meyers, Brooke A, Johnson, Sarah B, Harris, Angela L, Czako, Barbara, Cross, Jason B, Leonard, Paul G, Mseeh, Faika, Francesco, Maria E Di, Parker, Connor A, Wu, Qi, Bristow, Christopher A, Burke, Jason P, Carrillo, Caroline C, Carroll, Christopher L, Chang, Qing, Feng, Ningping, Gera, Sonal, Guang, Gao, Huang, Justin Kwang-Lay, Jiang, Yongying, Kang, Zhijun, Kovacs, Jeffrey J, Ma, Xiaoyan, Mandal, Pijus K, McAfoos, Timothy, Mullinax, Robert A, Peoples, Michael D, Ramamoorthy, Vandhana, Seth, Sahil, Suzuki, Erika, Williams, Christopher Conrad, Yu, Simon S, Zuniga, Andy M, Draetta, Giulio F, Marszalek, Joseph R, Heffernan, Timothy P, Kohl, Nancy E, Jones, Philip

“…Osimertinib, a third generation EGFR inhibitor, is a front-line therapy for EGFR mutated non-small lung cancer (NSCLC). The long-term effectiveness of…”
Get full text

Targeting Oxphos Pathway Against Ibrutinib Resistance to Mantle Cell Lymphoma by Liu, Yang, Bell, Taylor, Zhang, Hui, Sun, Yuting, Li, Carrie J, Feng, Ningping, Huang, Shengjian, Guo, Hui, Wang, Jack, Ahmed, Makhdum, Zhang, Victoria, Lam, Laura T, Nomie, Krystle, Zhang, Liang, Di Francesco, Maria E, Marszalek, Joe, Wang, Michael

“…Background: Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy that is initially responsive but ultimately relapses to frontline therapy. Ibrutinib,…”
Get full text

Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer by Lin, Yu-Hsi, Satani, Nikunj, Hammoudi, Naima, Pisaneschi, Federica, Leonard, Paul, Maxwell, David, Peng, Zhenghong, Link, Todd, Gilbert, Lee IV R., Bosajou, Ananth, Sun, Duoli, Marszalek, Joe, Sun, Yuting, McMurray, John S., Mandal, Pijus K., Francesco, Maria E. Di, Czako, Barbara, Wang, Alan, Bornmann, William, DePinho, Ronald A., Muller, Florian

“…Glycolysis inhibition is an active area of investigation for the treatment of cancer. However, few compounds have progressed beyond the cell culture stage. We…”
Get full text

Abstract C183: Pomhex: a cell-permeable high potency Enolase inhibitor with in vivo anti-neoplastic activity by Lin, Yu-Hsi, Marszalek, Joe, Sun, Yuting, Hammoudi, Naima, Leonard, Paul, Maxwell, David, Satani, Nikunj, Zhang, Peng, Link, Todd, Lee, Gilbert, Di Francesco, Maria E., Czako, Barbara, Want, Alan Y., DePinho, Ronald A., Muller, Florian L.

“…Glycolysis inhibition is an active area of investigation in cancer. However, few compounds have progressed beyond the cell culture stage. We have recently…”
Get full text